Business Description
Molecular Partners AG
ISIN : US60853G1067
Share Class Description:
STU:6ML0: ADRCompare
Compare
Traded in other countries / regions
MOLN.SwitzerlandMOLN.USA0QXX.UK6ML.Germany IPO Date
2021-06-23Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 52.28 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 5.58 | |||||
| Beneish M-Score | -1.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -16.9 | |||||
| 3-Year EBITDA Growth Rate | 8.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | -14.1 | |||||
| 3-Year Book Growth Rate | 13.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -4.75 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 39.66 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.66 | |||||
| 9-Day RSI | 52.15 | |||||
| 14-Day RSI | 53.07 | |||||
| 6-1 Month Momentum % | 33.12 | |||||
| 12-1 Month Momentum % | 2.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.33 | |||||
| Quick Ratio | 14.33 | |||||
| Cash Ratio | 13.76 | |||||
| Days Sales Outstanding | 145.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.1 | |||||
| Shareholder Yield % | 0.59 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1050.83 | |||||
| Net Margin % | -1042.84 | |||||
| FCF Margin % | -1053.7 | |||||
| ROE % | -37.46 | |||||
| ROA % | -33.76 | |||||
| ROIC % | -711.94 | |||||
| 3-Year ROIIC % | 6.58 | |||||
| ROC (Joel Greenblatt) % | -1187.49 | |||||
| ROCE % | -36.21 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 30.33 | |||||
| PB Ratio | 1.32 | |||||
| Price-to-Tangible-Book | 1.32 | |||||
| EV-to-EBIT | -1 | |||||
| EV-to-EBITDA | -1.04 | |||||
| EV-to-Revenue | 10.41 | |||||
| EV-to-FCF | -0.99 | |||||
| Price-to-Net-Current-Asset-Value | 1.37 | |||||
| Price-to-Net-Cash | 1.43 | |||||
| Earnings Yield (Greenblatt) % | -100 | |||||
| FCF Yield % | -30.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecular Partners AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.265 | ||
| EPS (TTM) (€) | -1.987 | ||
| Beta | 0.46 | ||
| Volatility % | 113.66 | ||
| 14-Day RSI | 53.07 | ||
| 14-Day ATR (€) | 0.432326 | ||
| 20-Day SMA (€) | 5.0675 | ||
| 12-1 Month Momentum % | 2.45 | ||
| 52-Week Range (€) | 3.04 - 9.8 | ||
| Shares Outstanding (Mil) | 36.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Molecular Partners AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Molecular Partners AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Molecular Partners AG Frequently Asked Questions
What is Molecular Partners AG(STU:6ML0)'s stock price today?
The current price of STU:6ML0 is €5.30. The 52 week high of STU:6ML0 is €9.80 and 52 week low is €3.04.
When is next earnings date of Molecular Partners AG(STU:6ML0)?
The next earnings date of Molecular Partners AG(STU:6ML0) is 2024-11-26 Est..
Does Molecular Partners AG(STU:6ML0) pay dividends? If so, how much?
Molecular Partners AG(STU:6ML0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers